Venetoclax
CD4+/CD56+ Hematodermic Neoplasm
French Innovative Leukemia OrganisationSmall moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 89/ 100
Competitive context
33 Active assets in the CD4+/CD56+ Hematodermic Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tagraxofusp French Innovative Leukemia Organisation | Phase 2 | BB |
Cyclophosphamide Fred Hutchinson Cancer Center | Phase 2 | BB |
Fludarabine Fred Hutchinson Cancer Center | Phase 2 | BB |
Methotrexate Therapeutic Advances in Childhood Leukemia Consortium | Phase 2 | BB |
Rituximab St. Jude Children's Research Hospital | Phase 2 | B |
View all 47 →
Same molecule, other indications
Venetoclax is also rated in:
chronic lymphocytic leukemia/small lymphocytic lymphomaActive
BB
Indicative · Phase 4
70 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →